Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults
Authors' conclusion
RAIR disease occurs in one-third of CAYA-PTC with pulmonary metastases. Younger patients (aged < 15 years) are more susceptible to RAIR status, which leads to unfavorable PFS and DSS.
Study context
- Population
- Patients with PTC aged ≤20 years, all with pulmonary metastases
- Participants
- 65 patients
- Exposure
- Radioactive iodine-refractory (RAIR) vs radioactive iodine-avid (RAIA) disease
- RAIRn = 20
- Outcome
- RAIR disease prevalence
Main finding
As reported in the abstract
RAIR disease among all patients
30.8%
20/65
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| RAIR disease, age <15vs 15-20 years | 3.500 (1.134–10.803) | P = 0.023 | |
| Progressive disease (independent predictor) | 10.008 (2.427–41.268) | P = 0.001 | |
| 0.050.21520Hazard ratio (log scale) |
| Outcome | P value |
|---|---|
| PFS and DSS (Kaplan-Meier)RAIR vs RAIA · lower PFS with RAIR | P < 0.001 |
| PFS and DSS (Kaplan-Meier)RAIR vs RAIA · lower DSS with RAIR | P = 0.039 |
| PFS in patients aged <15 yearsRAIR a risk factor for unfavorable PFS | P < 0.001 |
RAIR disease, age <15 vs 15-20 years
- No significant difference in pathologic characteristics between age groups
RET fusions and RAIR disease
- RET fusions most common alteration; no association with RAIR disease detected
- P = 0.210
- Gene alterations detected in 17 patients
Original publication
Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults. J Clin Endocrinol Metab. Published 13 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →